13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $43M | -$204M | 0.0% | -504.1% | -$188M | — | $602M |
| 2024 | $108M | -$97M | 0.0% | -101.9% | -$152M | — | $302M |
| 2023 | $113M | -$58M | 0.0% | -60.0% | -$21M | — | $200M |
| 2022 | $4M | -$162M | 0.0% | -4459.3% | -$129M | — | $88M |
| 2021 | $41M | -$122M | 0.0% | -310.1% | -$90M | — | $151M |
| 2020 | $20M | -$150M | 0.0% | -763.9% | -$117M | — | $184M |
| 2019 | $16M | -$194M | 0.0% | -1303.4% | -$192M | — | $147M |
| 2018 | $14M | -$147M | 0.0% | -1106.7% | -$33M | — | $175M |
| 2017 | $4M | -$102M | 0.0% | -2630.1% | -$103M | — | $143M |
| 2016 | $1M | -$56M | 0.0% | -5102.6% | -$37M | — | $150M |
| 2015 | — | -$19M | — | — | — | — | $161M |
| 2014 | — | -$5M | — | — | — | — | $1M |
| 2013 | — | -$3M | — | — | — | — | $439000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $38M | -$26M | 0.0% | -81.8% | -$60M | — | $545M |
| Dec '25 | — | -$53M | — | — | -$34M | — | $602M |
| Sep '25 | — | -$54M | — | — | -$45M | — | $196M |
| Jun '25 | $9M | -$50M | 0.0% | -606.5% | -$46M | — | $208M |
| Mar '25 | $9M | -$47M | 0.0% | -542.8% | -$63M | — | $243M |
| Dec '24 | — | $29M | — | — | -$44M | — | $302M |
| Sep '24 | — | -$62M | — | — | -$47M | — | $311M |
| Jun '24 | $20M | -$33M | 0.0% | -177.7% | -$28M | — | $154M |
| Mar '24 | $13M | -$32M | 0.0% | -274.8% | -$34M | — | $181M |
| Dec '23 | $29M | -$16M | 0.0% | -64.3% | -$34M | — | $200M |
| Sep '23 | $49M | $7M | 0.0% | 9.0% | -$35M | — | $140M |
| Jun '23 | $22M | -$21M | 0.0% | -106.2% | -$37M | — | $173M |
| Mar '23 | $13M | -$27M | 0.0% | -234.2% | $85M | — | $208M |
| Dec '22 | $1M | -$44M | 0.0% | -3516.0% | -$34M | — | $88M |
| Sep '22 | $285000 | -$39M | 0.0% | -13648.8% | -$26M | — | $97M |
| Jun '22 | $375000 | -$41M | 0.0% | -11243.7% | -$29M | — | $123M |
| Mar '22 | $2M | -$38M | 0.0% | -2176.8% | -$40M | — | $62M |
| Dec '21 | $2M | -$35M | 0.0% | -2045.9% | -$7M | — | $151M |
| Sep '21 | $36M | -$6M | 0.0% | -20.9% | -$28M | — | $124M |
| Jun '21 | $3M | -$39M | 0.0% | -1434.7% | -$10M | — | $144M |
How the market has priced WVE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Wave Life Sciences Ltd.'s revenue has grown 16.3% per year. These are computed facts, not advice.
As of FY2025, Wave Life Sciences Ltd. reported — of total debt against $602M of cash.
In FY2025, gross margin was —, operating margin -504.1%, and net margin -478.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.